Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions

Metastatic Hormone-Sensitive Prostate Cancer

Interventions

DRUG

Rezvilutamide

Rezvilutamide 240mg qd

DRUG

Rezvilutamide plus abiraterone

Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd

DRUG

Continue previous treatment

Continue using the previous treatment regimen for treatment.

All Listed Sponsors

lead

Jianbin Bi

OTHER

NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter